FRACTYL HEALTH, INC. — Form 8-K
Filed October 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Fractyl's REMAIN-1 pivotal trial (n=308) achieved its pre-specified 6-month co-primary endpoint with high statistical significance (p=0.0023). Revita-treated patients maintained 80% of GLP-1-induced weight loss versus 67% in sham controls (5.1% vs 8.2% regain). Post-hoc analysis showed patients with ≥20 cm duodenal ablation regained only 3.8% body weight vs 8.2% sham (53% reduction; p=0.003). No device- or procedure-related serious adverse events observed. De Novo FDA submission planned late Q4 2026; potential US launch early 2028.
Why this rating
Pivotal trial success validates core thesis for a clinical-stage company (~$49.6M market cap). Breakthrough Device designation + CPT code approval provide regulatory/reimbursement tailwinds. De Novo pathway and 2028 launch timeline credible. Second co-primary endpoint pending Q1 2027. Material de-risking but commercialization still uncertain.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-51.2% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $4.40 ▲ 102.36% | at our read · unknown $2.17 | +10 min · unknown $2.12 ▼ 2.53% | +30 min · unknown $2.17 ▼ 0.46% | +1 hr · unknown $2.10 ▼ 3.68% | +4 hrs · unknown $1.73 ▼ 20.69% |
The stock had already moved -50.58% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.